RGLS - Regulus Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1600
+0.0900 (+8.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.0700
Open1.1100
Bid0.8720 x 1800
Ask1.2500 x 900
Day's Range1.0700 - 1.1600
52 Week Range0.8000 - 9.4800
Volume41,376
Avg. Volume243,059
Market Cap12.463M
Beta (3Y Monthly)2.34
PE Ratio (TTM)N/A
EPS (TTM)-5.5870
Earnings DateMay 8, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.67
Trade prices are not sourced from all markets
  • Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019
    PR Newswire11 days ago

    Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019

    "We are pleased to be presenting preclinical data during this year's EASL International Liver Congress that we believe demonstrates the potential of our lead anti-miR-132 to be a promising therapeutic for the treatment of NASH," said Jay Hagan, President and Chief Executive Officer of Regulus. Details of the late breaker poster presentation are as follows and will be available for download at the time of presentation at http://regulusrx.com/publications.

  • Penny Stocks to Buy Using Technical Analysis for April 2019
    Investopedia19 days ago

    Penny Stocks to Buy Using Technical Analysis for April 2019

    As we near a turning of the tide in the markets, penny stocks could bounce around more quickly than usual, so traders should be extra alert.

  • ACCESSWIRE22 days ago

    Four Healthcare Stocks Getting a Boost on Thursday

    CORAL GABLES, FL / ACCESSWIRE / March 28, 2019 / The healthcare stock market has been a hotbed of excitement in the first few months of 2019 as companies in the industry have focused their efforts on developing innovative technologies and treatments for consumers. Consumers depend and expect healthcare companies to invest in new forms of drug treatments and other aspects of the care experience so that, when a patient needs care, they don't have to look very far. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Arcturus Therapeutics Ltd (ARCT), Sesen Bio Inc (SESN), and Regulus Therapeutics Inc (RGLS) are 4 healthcare companies making moves on Thursday.

  • Associated Presslast month

    Regulus: 4Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 98 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates
    PR Newswirelast month

    Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates

    LA JOLLA, Calif. , March 18, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Announces Transition of Research Leadership
    PR Newswirelast month

    Regulus Announces Transition of Research Leadership

    LA JOLLA, Calif., March 15, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the resignation of Dr. Timothy Wright, Chief Research and Development Officer, effective March 15, 2019.  Dr. Wright is leaving for personal reasons to pursue a new opportunity, and will continue to support Regulus as a scientific advisor.

  • Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
    PR Newswire3 months ago

    Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme

    Standard of care temozolomide as a single agent increased median survival by 27% vs. control, therefore the combination of RGLS5579 plus temozolomide demonstrated synergistic efficacy in this model. RGLS5579 has completed the clinical candidate screening process demonstrating appropriate preliminary safety and drug-like properties.

  • Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
    PR Newswire3 months ago

    Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study

    LA JOLLA, Calif., Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the preliminary results of a planned interim data analysis from the new mouse chronic toxicity study of RGLS4326 in development for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD. As previously reported by the Company in July 2018, and in consultation with FDA, the Company voluntarily paused its ongoing Phase 1 Multiple Ascending Dose ("MAD") study of RGLS4326 in healthy volunteers due to unexpected observations in the 27-week mouse chronic toxicity study.  The Company terminated that mouse study prematurely at week 14.  The study was run in parallel to the Phase 1 program to enable initiation of the Phase 2 program in ADPKD patients upon completion of the Phase 1 MAD study.

  • Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares
    Simply Wall St.4 months ago

    Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...

  • GlobeNewswire5 months ago

    Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme
    PR Newswire5 months ago

    Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme

    Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival LA JOLLA, Calif. , Nov. 19, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . ...

  • Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
    Zacks5 months ago

    Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 24.36% and -10.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press5 months ago

    Regulus: 3Q Earnings Snapshot

    The San Diego-based company said it had a loss of $1.18 per share. The biopharmaceutical company posted revenue of $18,000 in the period. In the final minutes of trading on Thursday, the company's shares ...

  • Regulus Reports Third Quarter 2018 Financial Results and Recent Updates
    PR Newswire5 months ago

    Regulus Reports Third Quarter 2018 Financial Results and Recent Updates

    $47 Million Restructured Sanofi Collaboration Executed Initiated New Chronic Mouse Toxicity Study for RGLS4326; Data Anticipated in Q1 2019 LA JOLLA, Calif. , Nov. 8, 2018 /PRNewswire/ --  Regulus Therapeutics ...

  • Regulus Announces Successful Restructuring of Sanofi Collaboration
    PR Newswire5 months ago

    Regulus Announces Successful Restructuring of Sanofi Collaboration

    Sanofi Will Assume Development of RG-012 for Alport syndrome LA JOLLA, Calif. , Nov. 6, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...

  • Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018
    PR Newswire6 months ago

    Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • ACCESSWIRE6 months ago

    3 Healthcare Stocks To Watch On Tuesday

    Healthcare stocks have helped during times like these. Three healthcare stocks to watch this week include Premier Health Group, Inc. (PHGRF)(PHGI.CN), Neovasc Inc. (NVCN), and Regulus Therapeutics Inc. (RGLS). Premier Health Group, Inc. (PHGRF)(PHGI.CN), continued to trade higher this week.

  • Benzinga6 months ago

    The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit 52-week highs in Monday's session. Down In The Dumps (Biotech stocks hitting 52-week ...

  • Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018
    PR Newswire6 months ago

    Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 22, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Regains Compliance with NASDAQ Listing Requirements
    PR Newswire6 months ago

    Regulus Regains Compliance with NASDAQ Listing Requirements

    LA JOLLA, Calif. , Oct. 18, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Therapeutics Announces Reverse Stock Split
    PR Newswire6 months ago

    Regulus Therapeutics Announces Reverse Stock Split

    The effective time of the reverse stock split was 5:00 p.m. ET on October 3, 2018.  The Company's shares will begin trading on a split-adjusted basis commencing upon market open on October 4, 2018. "Over the past several months, we have taken steps to reposition Regulus for long term sustainability.

  • Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference
    PR Newswire7 months ago

    Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference
    PR Newswire7 months ago

    Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Regulus Provides Pipeline Updates
    PR Newswire7 months ago

    Regulus Provides Pipeline Updates

    Hepatitis B virus (HBV) Programs: The Company has identified several microRNA targets that serve as host factors for the virus.  The Company's lead compound directed to one of the host microRNAs has demonstrated sub-nanomolar potency against HBV DNA replication and 95% reduction in HBsAg in in vitro studies.  The Company believes that targeting a host factor in the liver represents a unique mechanism of action for treatment of the virus compared to other programs in development and holds the potential for achieving a functional cure. The Company currently expects to file an IND for the HBV program in the second half of 2019, with the potential of achieving human proof-of-concept in a Phase 1 study. Glioblastoma multiforme (GBM) Program: The Company's lead anti-miR candidate targeting microRNA-10b demonstrated statistically significant improvements in survival as both a monotherapy as well as in combination with temozolamide (TMZ) in an orthotopic GBM animal model.